GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Eli Lilly stock plunges. To find out what lies ahead for Eli Lilly in this increasingly competitive environment, visit CDS.

Find insight on Roche Holding, Novo Nordisk, Eli Lilly and more in the latest Market Talks covering Health Care.